Detalhe da pesquisa
1.
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
Blood
; 139(26): 3722-3731, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35439295
2.
Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes.
Haematologica
; 109(4): 1289-1292, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855058
3.
Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma.
Br J Haematol
; 202(2): 434-436, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36999438
4.
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.
Blood Adv
; 8(2): 453-467, 2024 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37903325
5.
Genomic profiling of Mycosis Fungoides identifies patients at high risk of disease progression.
Blood Adv
; 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513135
6.
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Transplant Cell Ther
; 29(7): 430-437, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37031746
7.
Effective anti-BCMA retreatment in multiple myeloma.
Blood Adv
; 5(15): 3016-3020, 2021 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34351389
8.
Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia.
Leukemia
; 34(8): 2230-2233, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31988437